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doi:10.1016/j.jtcvs.2007.02.028bjective: We sought to evaluate the effect of a strict glycemic control protocol on
series of diabetic patients undergoing surgical myocardial revascularization.
ethods: Between January 2003 and June 2004, 300 diabetic patients undergoing
yocardial revascularization received a local protocol of insulin administration
protocol, group P). Patients were divided into 2 risk classes, according to their
dditive EuroSCORE value: low–moderate risk (0–4) and moderate–high risk
4). The logistic EuroSCORE algorithm was used to calculate the expected
robability of death. A control group was selected, including a series of 300
onsecutive diabetic patients (no protocol group, group NP) who underwent coro-
ary artery bypass grafting between March 2001 and September 2002, just before
he introduction of the protocol. A propensity analysis was performed to control for
election bias.
esults: Both groups showed similar EuroSCORE risk profiles: mean additive and
ogistic EuroSCORE values were 4.16 and 4.29 in group P versus 3.93 and 3.91 in
roup NP. Observed and expected mortalities of group P were 0.6% versus 1.8%
low–moderate risk), 2.5% versus 8.0% (moderate–high risk, P  .03), and 1.3%
ersus 4.3% (entire group, P .01). Observed and expected mortalities of group NP
ere 1.6% versus 1.9% (low–moderate risk), 8.3% versus 7.5% (moderate–high
isk), and 4.0% versus 3.9% (entire group). Logistic regression confirmed observed
ortality in group P to be significantly lower than the expected logistic EuroSCORE
ortality. After risk adjustment, the protocol allowed us to reduce the mortality
dds by 72% (odds ratio, 0.282; 95% confidence interval, 0.092–0.859; P  .03).
ubgroup analysis for moderate- to high-risk patients showed the protocol to
mprove mortality (odds ratio, 0.24; P  .05), whereas no significant improvement
as found in low- to moderate-risk patients. Addition of the propensity score to the
ultivariable analysis did not significantly displace P values and odds ratios.
ensitivity analysis of patients who underwent coronary artery bypass grafting
ithout additional procedures showed the protocol to maintain its protective effect
odds ratio, 0.15; P  .05).
onclusion: Optimal glucose control highly reduces EuroSCORE expected mortal-
ty in diabetic patients undergoing myocardial revascularization, especially in
oderate- to high-risk patients.
orldwide, there are more than 150 million adults estimated to have
diabetes mellitus (DM), and that number is expected to increase.1 Since
the first reports from the Framingham study, diabetes has been recog-
ized to be an independent risk factor for the development of coronary artery
isease,2 which represents the most common cause of death in diabetic patients.1
iabetic patients represent nearly 25% of revascularization procedures, coronary
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A
CDrtery bypass grafting (CABG) operations, or percutaneous
ransluminal coronary angioplasty, and they do worse after
ither type of chosen revascularization compared with non-
iabetic patients.3 Although diabetic patients frequently
ave concomitant risk factors, DM has been proved to be an
ndependent risk predictor of early4-6 and late6,7 mortality
fter CABG. In the Diabetes mellitus Insulin-Glucose infu-
ion in Acute Myocardial Infarction (DIGAMI) study
almberg and colleagues8 reported that glycemic control
y insulin infusions provided better long-term survival in
iabetic patients having experienced myocardial infarction
MI). Other works suggested that strict glycemic control can
mprove outcomes in diabetic patients undergoing
ABG,9,10 even in the setting of a general surgical intensive
are unit (ICU).11 In October 2002, a local protocol of
erioperative/in-hospital strict glycemic control in diabetic
atients started in our institution. Its efficacy has been
hown in a series of 200 consecutive diabetic patients un-
ergoing on-pump cardiac surgery.12 According to their
nsulin response, patients were divided into good (n  165)
nd poor (n  35) responders. The protocol enabled us to
ostoperatively attain a mean blood glucose concentration
f 8.21  2.28 mmol/L (148 41 mg/dL) in good respond-
rs and 11.54  3.00 mmol/L (208  54 mg/dL) in poor
esponders. Afterward, we sought to evaluate this protocol’s
ffect on the expected mortality of a diabetic patient population
ndergoing myocardial revascularization. The observed and
xpected mortalities were compared according to the Euro-
CORE risk evaluation model.13 Therefore, our primary goal
as to estimate the effect of strict glycemic control on the
uroSCORE expected mortality. Nevertheless, we choose to
nclude a control group to verify that the EuroSCORE model
id not overestimate mortality. Reduction of potential bias was
ttempted by adding a propensity score analysis.14,15
aterials and Methods
atients
his study was approved by our ethical committee (Comité de
rotection des Personnes se Prêtant à la Recherche Biomédicale,
CPPRB Pitié-Salpêtrière, Paris, France). Although patient
Abbreviations and Acronyms
BGL  blood glycemic level
CABG coronary artery bypass grafting
COPD  chronic obstructive pulmonary disease
DM  diabetes mellitus
ICU  intensive care unit
ITA  internal thoracic artery
LVEF  left ventricular ejection fraction
O/E  observed/expected ratio
OR  odds ratioare conformed to the standard procedure currently used at our F
0 The Journal of Thoracic and Cardiovascular Surgery ● July 2nstitute, written informed consent was obtained from each patient
ncluded in this study. Since October 2002, all patients with DM
ndergoing cardiac surgery at our institution have been receiving
protocol of insulin administration for glycemic control. A
-month period was needed to ensure full implementation of the
rotocol and to achieve nursing compliance. All patients with DM
ndergoing CABG between January 2003 and June 2004, alone or
n association with other procedures, were included in this study
protocol group, group P; n  300). The following preoperative
ariables, needed for EuroSCORE estimation, were prospectively
ntered into our database: age, sex, chronic obstructive pulmonary
isease (COPD) on therapy, extracardiac arteriopathy, neurologi-
al dysfunction disease, previous cardiac surgery, serum creatinine
evels of greater than 200 mol/L, active endocarditis, critical
reoperative status, unstable angina, left ventricular ejection frac-
ion (LVEF) of 30% to 50% or less than 30%, recent MI (90
ays), systolic pulmonary artery pressure of greater than 60 mm
g, emergency, previous coronary angioplasty, number of dis-
ased vessels, left main coronary trunk stenosis of greater than
0%, major cardiac procedures in addition to CABG, operation on
he thoracic aorta, and postinfarction septal rupture. Other preop-
rative variables entered were type of DM therapy (oral drugs or
nsulin), body mass index, previous coronary angioplasty, number
f diseased vessels, and left main coronary trunk stenosis of
reater than 50%. The patients were divided into 2 risk classes,
ccording to their additive EuroSCORE values: low–moderate risk
EuroSCORE, 0-4) and moderate–high risk (EuroSCORE, 4).
he logistic EuroSCORE algorithm was used to assign to every
atient an expected death probability. A mean logistic EuroSCORE
alue was calculated for each risk class, aiming to compare ob-
erved and expected mortality.
As previously anticipated, a control group was selected includ-
ng a series of 300 consecutive diabetic patients (no protocol
roup, group NP) who underwent CABG between March 2001 and
eptember 2002 just before the introduction of the protocol. Pre-
perative characteristics of study groups and patient risk profiles
re shown in Table 1.
rotocol
ntil October 2002, glucose control started on the patient’s arrival
t the ICU. No attempt to control blood glycemic levels (BGLs)
as performed the day before surgical intervention and even
uring surgical intervention. Once in the ICU, fast-acting insulin
Actrapid HM; Novo Nordisk Pharmaceutique, Puteaux, France)
as administered subcutaneously, according to the following pro-
ocol: less than 6.66 mmol/L (120 mg/dL), 0 U; 6.66 to 8.33
mol/L (120–150 mg/dL), 2 U; 8.38 to 9.99 mmol/L (151–180
g/dL), 4 U; 10.05 to 11.66 (181–210 mg/dL), 6 U; and greater
han 11.66 mmol/L (210 mg/dL), 8 U.
Since October 2002, all treated diabetic patients undergoing
ardiac procedures at our institution have been receiving a protocol
o standardize the titration of insulin therapy during the perioper-
tive period. This protocol, which has been extensively described
lsewhere,12 has not changed during the timeframe of the study.
riefly, all preoperative diabetic therapies were withdrawn the
vening before the operation and were substituted with 0.15 U/kg
ubcutaneous intermediary insulin (Umuline NPH; Lilly, Suresnes,
rance), with additional subcutaneous fast-acting insulin (Actrapid
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A
CDM) according to BGL. In addition to the implementation of this
rotocol, an infusion of dextrose solution was started (5 g/h). After
GL measurement, all patients systematically received a further
ubcutaneous injection of 0.15 U/kg intermediary insulin on the
orning of the operation (Umuline NPH). During the intraopera-
ive period, the infusion of dextrose was maintained at the same
ate (ie, 5 g/h), and an aggressive insulin therapy based on con-
inuous infusion of fast-acting insulin (Actrapid HM) was initiated
s soon as BGL exceeded 9.99 mmol/L (180 mg/dL); BGLs were
easured immediately after the induction of anesthesia and there-
fter at 30-minute intervals. Subsequently, its infusion rate was
itrated according to a protocol (see Appendix 1) modified from the
ortland protocol.9 The objective of the current protocol was to
aintain an intraoperative blood glucose concentration of between
.33 and 11.10 mmol/L (150-200 mg/dL). During the postopera-
ive period, all patients were aggressively treated with either sub-
utaneous or continuous intravenous insulin therapy to maintain a
GL of less than 7.77 mmol/L (140 mg/dL). Throughout their stay
n the ICU, BGL determination was performed on an hourly
ABLE 1. Preoperative characteristics
All
o. of patients 600
ge (y) 66 10
ex (F) 142 (24%)
iabetic control
Oral 437 (73%)
Insulin 163 (27%)
MI 28  5
MI 30 149 (25%)
OPD on therapy 29 (5%)
xtracardiac arteriopathy 100 (17%)
eurological dysfunction disease 27 (5%)
revious cardiac surgery 15 (3%)
erum creatinine 200 mol/L 20 (3%)
ctive endocarditis 0 (0%)
ritical preoperative status 8 (1%)
nstable angina 61 (10%)
VEF dysfunction (30%-50%) 199 (33%)
VEF dysfunction (30%) 19 (3%)
ecent MI (90 d) 31 (5%)
ystolic PA pressure 60 mm Hg 0 (0%)
mergency 47 (8%)
revious PTCA 105 (18%)
eft main trunk 50% 121 (19%)
o. of diseased vessels 2.6 0.6
ajor associated procedures 92 (15%)
peration on thoracic aorta 1 (0.2%)
ostinfarction septal rupture 1 (0.2%)
uroSCORE (additive) 4.04 2.90
uroSCORE (logistic) 4.10 5.62
uroSCORE 0-4 372 (62%)
uroSCORE 4 228 (38%)
MI, Body mass index; COPD, chronic obstructive pulmonary disease; LV
rtery; PTCA, percutaneous transluminal coronary angioplasty.asis. Once out of the ICU, patients were treated according to m
The Journal of Thorache following protocol: intermediary insulin (Umulin NPH) was
dministered subcutaneously twice daily (0.15 IU/kg). Addi-
ionally, BGLs were adjusted every 4 hours by using subcuta-
eous fast-acting insulin (Actrapid HM): less than 6.11 mmol/L
110 mg/dL), 0 U; 6.11 to 7.99 mmol/L (110-144 mg/dL), 2 U;
.05 to 9.93 mmol/L (145–179 mg/dL), 4 U; 9.99 to 12.15
mol/L (180 –219 mg/dL), 6 U; and greater than 12.21 mmol/L
220 mg/dL), 8 U.
tatistical Analysis
nivariate analysis for assessment of the relationships between
otential prognostic factors and mortality was performed by using
2 tests for categoric variables and Student t tests for continuous
ariables. Death probability was calculated for each patient ac-
ording to the EuroSCORE logistic model. A logistic regression
as performed, with the logit of death probability and protocol
tatus as potential prognostic factors. Separate subgroup logistic
egressions were performed for low- to moderate-risk and
Group P Group NP P value
300 300
66  10 66  10 .80
69 (23%) 73 (24%) .70
212 (71%) 225 (75%) .23
88 (29%) 75 (25%) .23
27 4 28 6 .66
75 (25%) 74 (25%) .92
23 (8%) 6 (2%) .01
58 (19%) 42 (14%) .08
16 (5%) 11 (4%) .32
7 (2%) 8 (3%) .79
7 (2%) 13 (4%) .17
0 (0%) 0 (0%)
6 (2%) 1 (1%) .15
37 (12%) 24 (8%) .08
96 (32%) 103 (34%) .54
5 (2%) 14 (5%) .04
26 (9%) 5 (2%) .01
0 (0%) 0 (0%)
21 (7%) 26 (5%) .45
51 (17%) 54 (18%) .75
62 (21%) 59 (20%) .76
2.5  0.6 2.6  0.6 .20
39 (13%) 53 (18%) .11
1 (0.3%) 0 (0%) .32
1 (0.3%) 0 (0%) .32
4.16  2.98 3.93  2.90 .34
4.29  6.32 3.91  4.83 .41
180 (60%) 192 (64%) .31
120 (40%) 108 (36%) .31
ft ventricular ejection fraction; MI, myocardial infarction; PA, pulmonaryEF, leoderate- to high-risk patients. To measure a model’s discrimina-
ic and Cardiovascular Surgery ● Volume 134, Number 1 31
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A
CDion, c-statistics (area under the receiver operating characteristic
urve) were used, and the Hosmer–Lemeshow test was used for
oodness-of-fit assessment. A propensity analysis was performed
o control for selection bias: a propensity score was calculated for
ach patient by using logistic regression modeling, which esti-
ated the probability for a patient to receive a protocol of strict
lycemic control. Variables used to determine the propensity score
ere selected among preoperative and intraoperative variables that
ere significant at a two-tailed nominal P value of less than .20:
VEF, COPD, recent MI, extracardiac arteriopathy, critical pre-
perative status, unstable angina, serum creatinine level of greater
han 200 mol, bilateral thoracic artery revascularization, major
ssociated procedures, and crossclamping duration time. The pro-
ensity score was subsequently regressed as an independent co-
ariate by means of quintile stratification in the multivariable
ogistic regression model, including the logit of death probability
nd protocol status. A sensitivity analysis was carried out for
atients who underwent CABG without additional procedures:
new propensity score was recalculated and subsequently re-
ressed in the same way as described above. Data are expressed
s means  standard deviation for continuous variables and
umbers and percentages for qualitative variables. All P values
ere 2 tailed. All statistical analyses were performed with the
AS V8 statistical package (SAS Institute, Inc, Cary, NC).
ajor Outcomes
he primary outcome was in-hospital mortality. Causes of
orbidity were defined as follows: (1) cardiac (low cardiac
utput and/or hypotension treated with an intra-aortic balloon
ump and/or 2 intravenous inotropes or vasopressors over
ore than 24 hours, malignant arrhythmia [asystole, ventricular
achycardia, or ventricular fibrillation] requiring cardiopulmo-
ary resuscitation, antiarrhythmia therapy or defibrillator im-
lantation); (2) respiratory (mechanical ventilation for 48
ours, reintubation, tracheostomy); (3) neurological (focal brain
njury with permanent functional deficit, irreversible encepha-
opathy); (4) renal (acute renal failure necessitating dialysis);
nd (5) infectious (septic shock with positive blood culture
esults, deep sternal or leg wound infection requiring intrave-
ous antibiotics and/or surgical debridement).
esults
reoperative Characteristics
uroSCORE risk profiles were similar in both groups. Mean
dditive and logistic EuroSCORE values were, respectively,
.16  2.98 and 4.29  6.32 in group P versus 3.93  2.90
nd 3.91 4.83 in group NP. Furthermore, the distribution of
atients across the 2 risk classes was similar in both groups:
80 (60%) patients in group P versus 192 (64%) in group NP
ere in the low- to moderate-risk class (EuroSCORE, 0-4),
nd 120 (40%) in group P versus 108 (36%) in group NP were
n the high- to moderate-risk class (EuroSCORE, 4). The
ollowing preoperative characteristic variables were signifi-
antly different in the 2 groups: COPD, LVEF of less than
0%, and recent MI. i
2 The Journal of Thoracic and Cardiovascular Surgery ● July 2lucose Control
ean BGL trends of both groups are shown in Figure 1.
reoperative mean BGLs were not significantly different
etween the 2 groups: 9.19  3.90 mmol/L (166  70
g/dL) in group P versus 9.55  1.28 (172  23 mg/dL) in
roup NP (P  0.30). The BGLs at the end of the operation
nd on postoperative days 1 and 2 were significantly lower
n group P. Moreover, the lower standard error of mean
ostoperative BGLs means a more uniform control of gly-
emic levels in group P (Table 2).
ostoperative Results
etails of operative data and associated procedures, as well
s postoperative mortality and morbidity, are presented in
able 2.
The most important difference between the 2 groups was
he number of patients having a bilateral internal thoracic
rtery (ITA) revascularization: 134 (45%) in group P versus
8 (13%) in group NP (P .01). This difference reflects our
ore recent policy of extensive arterial revascularization
sing both ITAs, even in diabetic patients.
Seminal cause of death in group P was cardiogenic shock
n 3 (1%) patients and pneumonia in 1 (0.3%) patient. Main
ause of death in group NP was cardiogenic shock in 7
2.3%) patients, cardiac arrhythmia in 2 (0.7%) patients,
espiratory distress syndrome in 2 (0.7%) patients, and
troke in 1 (0.3%) patient. Overall mortality was 1.3%
4 patients) in group P versus 4.0% in group NP (12 pa-
ients; P  .05). Death occurred more frequently in patients
ho underwent CABG with associated procedures: 1% for
solated CABG versus 3% for CABG and associated pro-
edures in group P, 2% for isolated CABG versus 13% for
ABG and associated procedures in group NP, and 1% for
ig 1. Mean blood glycemic level (BGL) trends. D 1, Day before
he operation, P  .30; DOS, day of the operation, P < .001; POD
and POD 2, postoperative days 1 and 2, P < .001.solated CABG versus 9% for CABG and associated pro-
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A
CDedures in the whole population. There was no difference of
orbidity between the 2 groups.
isk Factors for Operative Mortality
ccording to univariate analysis, the following variables
ielded as a risk factor for operative mortality. Among
reoperative characteristics not used for EuroSCORE risk
stimation, only the absence of a protocol yielded as a
redictor of mortality (P  .0426). Among single variables
ntered in the EuroSCORE model, extracardiac arteriopathy
P  .0234), previous cardiac surgery (P  .0094), serum
reatinine level of greater than 200 mol/L (P  .0384),
VEF of less than 30% (P  .0001), and major associated
rocedures, (P  .0001) were risk factors for operative
ortality. Additive and logistic EuroSCORE values were
onfirmed to be excellent predictors of mortality (P .0008
able 2. Operative data and postoperative results
All
PB time (min) 71 29
rossclamp time (min) 53 24
ff pump 30 (5%)
o. of grafts per patient 2.6 0.
o ITA 14 (2%)
ingle ITA 414 (69%
ilateral ITA 172 (29%
ssociated procedures 92 (15%
AVR 45 (8%)
AVR  MVR 3 (1%)
AVR  mitral repair 2 (0.3%
MVR 2 (0.3%
Mitral repair 9 (2%)
Carotid endarterectomy 26 (4%)
Aorta/brachiocephalic trunk artery graft 1 (0.2%
Bentall procedure 1 (0.2%
Septal myomectomy 1 (0.2%
Septal defect closure 1 (0.2%
Myxoma resection 1 (0.2%
ortality 16 (3%)
ean blood glucose level (mmol/L)
Evening before operation 9.37 4.
Day of operation 8.61 3.
Postoperative day 1 10.55 3.
Postoperative day 2 8.80 3.
Mean postoperative blood glycemic level 9.29 2.
orbidity 77 (13%
Cardiac 55 (9%)
Pulmonary 27 (5%)
Neurological 15 (3%)
Renal 8 (1%)
Infectious 41 (7%)
ediastinitis 24 (4%)
PB, Cardiopulmonary bypass; ITA, internal thoracic artery; AVR, aortic vnd P  .0104). Among operative data, no use of ITAs (
The Journal of ThoracP  .0001) and cardiopulmonary bypass and crossclamp-
ng duration times (P  .0031 and P  .0009) were risk
actors for operative mortality. The use of both ITAs for
yocardial revascularization did not affect operative mor-
ality at univariate analysis (P  .37).
xpected and Observed Mortality
omparisons between mean observed and expected mor-
alities are shown in Figure 2. Observed mortality in
roup P was lower than the expected mortality for the
ntire group, as well as for each risk class: 0.6% versus
.8% (low–moderate risk), 2.5% versus 8.0% (moderate–
igh risk, P  .03), and 1.3% versus 4.3% (entire group,
 .01). On the other hand, there was no difference
etween observed and expected mortality in group NP:
.6% versus 1.9% (low–moderate risk), 8.3% versus 7.5%
Group P Group NP P value
72  29 70  30 .40
55  25 52  24 .08
13 (4%) 17 (6%) .45
2.7  0.9 2.6  0.8 .18
5 (2%) 9 (3%) .28
161 (54%) 253 (84%) .01
134 (45%) 38 (13%) .01
39 (13%) 53 (18%) .11
22 (7%) 23 (8%) .88
1 (0.3%) 2 (1%) .56
1 (0.3%) 1 (0.3%) 1.00
0 (0%) 2 (1%) .16
3 (1%) 6 (2%) .31
9 (3%) 17 (6%) .11
0 (0%) 1 (0.3%) .32
1 (0.3%) 0 (0%) .32
1 (0.3%) 0 (0%) .32
1 (0.3%) 0 (0%) .32
0 (0%) 1 (0.3%) .32
4 (1.3%) 12 (4.0%) .04
9.19  3.90 9.56  4.42 .30
7.89  2.52 9.40  3.92 .001
8.94  2.60 12.29  4.45 .001
7.72  2.42 9.89  3.34 .001
8.19  1.58 10.48  2.62 .001
41 (14%) 36 (12%) .54
30 (10%) 25 (8%) .48
16 (5%) 11 (4%) .32
7 (2%) 8 (3%) .79
3 (1%) 5 (2%) .48
24 (8%) 17 (6%) .26
14 (5%) 10 (3%) .40
eplacement; MVR, mitral valve replacement.8
)
)
)
)
)
)
)
)
)
)
16
35
97
11
43
)moderate–high risk), and 4.0% versus 3.9% (entire group).
ic and Cardiovascular Surgery ● Volume 134, Number 1 33
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A
CDogistic regression showed the EuroSCORE to overestimate
ortality in patients receiving the protocol (Ucal 2.183, P
03), but it confirmed the EuroSCORE to well predict mortality
or patients not receiving the protocol (Ucal  0.0854). After
isk adjustment for the EuroSCORE logistic value, multi-
ariable analysis showed the protocol of glycemic control to
educe the odds of mortality by 72% (odds ratio [OR],
.282; 95% confidence interval, 0.092-0.859; P  .03).
ubgroup analysis showed the moderate- to high-risk group
f patients to receive the greatest benefit from strict glyce-
ic control. For patients with a EuroSCORE of greater than
, the protocol improved mortality (OR, 0.24; P  .05),
hereas no significant improvement was found in low- to
oderate-risk patients (OR, 0.36; P  .3819). When in-
luded in the multivariable analysis, the use of both ITAs
or myocardial revascularization did not affect operative
ig 2. A, Comparison between observed and expected mortality
n group P. 2 Test: *P  .03, **P  .01. B, Comparison between
bserved and expected mortality in group NP.ortality (P  .3186). S
4 The Journal of Thoracic and Cardiovascular Surgery ● July 2Addition of the propensity score to the multivariable
nalysis did not significantly displace P values and ORs,
ith the protocol being associated with an OR of 0.24
P  .03). Sensitivity analysis of patients who underwent
ABG without additional procedures showed the proto-
ol to maintain its protective effect with an OR of 0.15
 P  .05, Table 3).
iscussion
mportance of Glucose Control
hese findings clearly demonstrate that optimal glucose
ontrol reduces EuroSCORE expected mortality in diabetic
atients undergoing CABG. Much evidence has recently
hown that glucose control might play a key role in periop-
rative care of diabetic coronary patients. Moreover, peri-
perative hyperglycemia has been recognized as an inde-
endent predictor for outcome in diabetic12,16,17 and even in
ondiabetic17 patients.
Although adequate glycemic control has been found to
e efficiently achieved by a steady infusion of insulin,10
e chose an intermittent dosing performed during the
perative period; the infusion rate of insulin was subse-
uently titrated according to a protocol modified from the
ortland protocol. Our results, as in the work of Furnary
nd coworkers,9 confirm that a better control of glucose
evels, achieved by means of a protocol of insulin admin-
stration, reduces mortality in diabetic patients; the au-
hor accounts for this mortality reduction by a significant
eduction in cardiac-related mortality. It still remains
nclear whether strict glycemic control improves early
linical outcomes by preventing the detrimental effects of
igh blood glucose concentrations. The beneficial effects
f glycemic control might be directly related to the
etabolic effects of insulin. Maintenance of normogly-
emia during cardiac procedures has been claimed to be
nattainable, even with intensive insulin therapy, which,
n the other hand, could be harmful by initiating hypo-
lycemia.18 As Carvalho and associates19 advocate, we
tarted our protocol on overnight fasting together with
extrose infusions: indeed, administration of glucose and
nsulin before surgical intervention is different from most
nsulin protocols, which are initiated at the time of the
peration.9,10 Our approach, coupled with the withdrawal
f any preoperative treatment, allowed us to achieve
ot only tight glycemic control but also more uniform
ontrol of glycemic variations, as suggested by the lower
tandard error of postoperative BGLs in group P. More-
ver, starting infusion on the evening before the opera-
ion means an earlier beginning of insulin therapy. In-
eed, mortality reduction in the study by Van der Berghe
nd colleagues11 was evident only among patients who
emained in the ICU for 5 days or longer. Hence, as
chricker and Carvalho argued,20 we also think that an
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CDarlier and more aggressive approach might further im-
rove early outcomes.
bserved and Expected Mortality
ince the introduction of a protocol for perioperative control
f glycemic levels, we have quantified its effect on patients’
utcomes. Therefore we chose the EuroSCORE risk strati-
cation algorithm, the most rigorously evaluated scoring
ystem in cardiac surgery,21 with an excellent discrimina-
ory power to predict 30-day mortality for patients under-
oing CABG22 and even valve surgery.23 The additive
uroSCORE model13 was used to divide patients according to
heir risk values and to compare risk profiles between the 2
roups. To compare observed and expected deaths, we chose
he Logistic EuroSCORE model.24,25 Recently, EuroSCORE
as been claimed to overestimate mortality.26 Jin and Grunk-
meier27 suggested to recalibrate the logistic EuroSCORE
odel by setting the logistic probability equal to the ratio of
otal observed deaths to predicted deaths (O/E ratio). Knowing
hat the O/E ratio in group NP, our referring population, is
.0/3.9  1, we assumed the model did not need to be
ecalibrated.
Simple univariate comparisons on the basis of mean ob-
erved and expected mortalities demonstrate that observed and
xpected mortalities in group NP are quite the same, whereas
bserved mortality in group P is significantly lower than
he expected mortality. Furthermore, as recommended,28 we
erformed a new logistic regression with the logit of
uroSCORE death probability as a risk factor: the protocol
f insulin administration highly improved outcomes in dia-
etic patients, reducing by 72% the probability of death
OR, 0.28; 95% confidence interval, 0.092-0.859). These
esults were not significantly displaced by the addition of a
able 3. Multivariable analysis of mortality in patients with
Variable OR
uroSCORE 0-4
Protocol 0.361
EuroSCORE 20.076
uroSCORE 4
Protocol 0.236
EuroSCORE 2.809
hole population
Protocol 0.282
EuroSCORE 2.752
hole population*
Protocol 0.241
EuroSCORE 2.759
ABG only†
Protocol 0.155
EuroSCORE 2.78
R, Odds ratio; 95% CI, 95% confidence interval; CABG, coronary artery byp
Sensitivity analysis: patients receiving coronary artery bypass grafting wropensity score in the model. u
The Journal of ThoracBoth univariate and multivariate analyses showed the
rotocol to significantly improve outcomes in moderate- to
igh-risk patients (EuroSCORE, 4). Moreover, these re-
ults outlined that higher-risk patients receive the greatest
enefit from a strict glycemic control, resulting in a high
mproved O/E ratio. Indeed, overall mortality reduction is
ostly explained by outcomes improvements in such
atients.
However, statistically speaking, outcome improvements
n low-risk patients are difficult to effect, because the mor-
ality rate in such patients is obviously already low. Finally,
e do not definitively know whether tight glycemic control
n lower-risk patients is not useful at all or its benefits are
imply too difficult to demonstrate.
ilateral ITA Revascularization
ecently, we adopted a policy of extensive arterial revas-
ularization29 using both ITAs, even in diabetic patients, but
his approach did not have a significant effect on operative
ortality. Thoracic arteries were harvested as skeletonized
rafts to minimize sternal devascularization and reduce the
isk of mediastinitis.30 It has been demonstrated that glucose
ontrol reduces the risk of sternal wound infection.31,32 We
ould not appreciate this positive effect, probably because it
as counterbalanced in group P by the higher proportion of
atients undergoing a bilateral ITA revascularization, a
ell-known risk factor for mediastinitis.33
ABG and Associated Procedures
he two most important works on preoperative glycemic
ontrol in diabetic patients undergoing coronary surgery9,10
ere focused on a homogenous population of patients un-
ergoing isolated CABG. Sensitivity analysis of patients who
betes mellitus undergoing coronary artery bypass grafting
95% CI P value c-Statistics
0.830
0.09-0.86 .3819
0.84-476.90 .0635
0.788
0.06-0.96 .0441
1.49-5.29 .0014
0.833
0.09-0.86 .0260
2.26-3.35 .0001
0.839
0.06-0.90 .0344
2.21-3.43 .0001
0.763
0.02-0.84 .0310
2.18-3.55 .0001
rafting. *Whole population after addition of propensity score in the model.
t additional procedures after addition of propensity score in the model.dia
ass gnderwent CABG without additional procedures showed the
ic and Cardiovascular Surgery ● Volume 134, Number 1 35
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A
CDrotocol to maintain its protective effect. We included pa-
ients undergoing CABG in association with other proce-
ures because the inclusion of more complex patients in-
reased risk profiles and enhanced outcome differences over
relatively short period, 3 years in this study. This might
urther reduce the effect of all minute nonmeasurable im-
rovements in anesthesia, operative technique, and postop-
rative care that contribute to the reduction of early mortal-
ty over a longer period. Combined procedures were
ssociated with a higher EuroSCORE value, and as ex-
ected, death occurred more frequently in such patients.
ssociated procedures did not carry a dramatically higher
ortality in group P, probably because of the protective
ffect of the strict glycemic control on higher-risk patients,
esulting in a highly improved O/E ratio.
imits
lthough the study was prospectively designed, the com-
arison between groups P and NP was nonrandomized. A
etter control of glucose levels was known to have positive
ffects on patient outcomes, and therefore we considered a
andomized study design unethical. We added a propensity
core analysis to limit bias of nonrandomized comparison.
We do not know why morbidity and mortality outcomes
id not follow the same improvement trend. We could
peculate that the absence of improvements in morbidity
utcomes between the 2 groups should be explained by the
omposite nature of morbidity criteria and by the prospec-
ive design of the protocol study group, probably resulting
n a better detection and collection of morbidity events.
It is well known that infections should have been reduced
y a better glycemic control.31,32 We think that the lack of
ifference between the 2 groups might take into account the
ighest rate of bilateral ITA harvesting in the protocol
roup.
Finally, although our results showed a clear benefit for
atients receiving the protocol, our specific method of gly-
emic control might not be considered the standard practice
n most centers: a good nursing compliance is mandatory,
nd furthermore, the multiple steps required for the proto-
ol, even before surgical intervention, might not be easy to
ollow.
onclusions
iabetes represents one of the most frequent comorbidities
n patients undergoing CABG. Fortunately, recent evidence
howed that a tight glucose control could improve outcomes
n such patients, and we could quantify this mortality re-
uction, with an OR of 0.28. Higher-risk patients receive the
reatest benefit from a strict glycemic control, resulting in a
igh improved O/E ratio. This approach allowed us to
erform CABG in diabetic patients, half of whom had
ilateral ITA grafting with 1.3% operative mortality, a
1
6 The Journal of Thoracic and Cardiovascular Surgery ● July 2gure not much higher than the 1.0% in-hospital mortality
ecently reported in a series of 1142 diabetic patients un-
ergoing angioplasty in the state of New York.34
Therefore, optimal glucose control should become a
idespread gold standard of perioperative care in diabetic
atients. Further studies need to be performed to eventually
ntegrate DM and its control in the EuroSCORE risk strat-
fication algorithm.
We thank Martine Collomb for her kindly English revision of
he article.
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ppendix 1. Intraoperative Insulin Protocol
he infusion of insulin was initiated according to the following
rotocol: less than 9.99 mmol/L (180 mg/dL), 0 U/h; 9.99 to 12.21
mol/L (180–220 mg/dL), 1 U/h; 12.27 to 13.82 mmol/L (221–
49 mg/dL), 2 U/h; and greater than 13.82 mmol/L (249 mg/dl), 3
/h. Subsequently, blood glucose concentrations were measured
very 30 minutes, and the insulin infusion rate was titrated accord-
ng to the following protocol: less than 7.77 mmol/L (140 mg/dL).
ate of infusion was maintained at 0 until 9.99 mmol/L (180
g/dL). Then the insulin infusion was restarted at a 50% rate of
he previous infusion: 7.77 to 9.93 mmol/L (140–179 mg/dL;
ecrease the rate by 0.5 U/h); 9.99 to 12.21 mmol/L (180–220
g/dL; no change in the infusion rate); 12.27 to 13.82 mmol/L
221–249 mg/dL; if the blood glucose concentration was less than
n the last test, the rate of infusion was unchanged, and if the blood
lucose concentration was greater than in the last test, the infusion
ate was increased by 0.5 U/h); 13.88 mmol/L or greater (250
g/dL; the rate of infusion was increased by 1 U/h). If the blood
lucose concentration did not decrease after 3 successive mea-
ures, the insulin infusion rate was doubled.
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